Y-mAbs Therapeutics (Y-mAbs Therapeutics) Days Sales Outstanding : 80.71 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics Days Sales Outstanding?

Y-mAbs Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $20.66 Mil. Y-mAbs Therapeutics's Revenue for the three months ended in Dec. 2023 was $23.36 Mil. Hence, Y-mAbs Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 80.71.

The historical rank and industry rank for Y-mAbs Therapeutics's Days Sales Outstanding or its related term are showing as below:

YMAB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.6 Med: 75.28 Max: 80.66
Current: 78.9

During the past 8 years, Y-mAbs Therapeutics's highest Days Sales Outstanding was 80.66. The lowest was 56.60. And the median was 75.28.

YMAB's Days Sales Outstanding is ranked worse than
53.99% of 889 companies
in the Biotechnology industry
Industry Median: 71.97 vs YMAB: 78.90

Y-mAbs Therapeutics's Days Sales Outstanding increased from Dec. 2022 (31.60) to Dec. 2023 (80.71).

Y-mAbs Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Y-mAbs Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Days Sales Outstanding Chart

Y-mAbs Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

80.66

56.60

75.28

Y-mAbs Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															31.60	70.37	83.15	84.75	80.71

Competitive Comparison of Y-mAbs Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Y-mAbs Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Y-mAbs Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Y-mAbs Therapeutics's Days Sales Outstanding falls into.

Y-mAbs Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Y-mAbs Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (12.531	+	22.454)	/	2 )	/	84.819	*	365
=	17.4925					/	84.819	*	365
=	75.28

Y-mAbs Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (18.874	+	22.454)	/	2 )	/	23.363	*	365 / 4
=	20.664					/	23.363	*	365 / 4
=	80.71

Y-mAbs Therapeutics (NAS:YMAB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Y-mAbs Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

230 Park Avenue, Suite 3350, New York, NY, USA, 10169

Website

https://www.ymabs.com

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.

Executives

Thomas Gad	director, officer: President and Chairman	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Biotech Aps Wg	10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Johan Wedell-wedellsborg	director, 10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Michael J Rossi	director, officer: President & CEO	230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Vignesh Rajah	officer: SVP and CMO	HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Bo Kruse	director, officer: EVP, CFO, Secy & Treas.	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Susan Laura Smith	officer: Senior Vice President, CCO	5 OVERLOOK CT, LAMBERTVILLE NJ 08530
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus	director, officer: Chief Executive Officer	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed	officer: Sr. VP and CSO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman	officer: Sr. VP and CCO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gregory S Raskin	director	C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169